SCHEMBL6525542

SCHEMBL6525542

COC(=O)C=Cc1n[nH]c2cc(C=C3C(=O)Nc4ccccc43)ccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK4 O00444 2/20 0.47
PLK1 P53350 2/20 0.47
DHFR P00374 1/20 0.47
ERBB2 P04626 4/20 0.46
PIM1 P11309 1/20 0.45
PDGFRB P09619 5/20 0.45
RET P07949 1/20 0.45
FLT3 P36888 1/20 0.45
PSEN1 P49768 1/20 0.45
PSEN2 P49810 1/20 0.45
APH1B Q8WW43 1/20 0.45
NCSTN Q92542 1/20 0.45
APH1A Q96BI3 1/20 0.45
PSENEN Q9NZ42 1/20 0.45
GSK3B P49841 1/20 0.44
EGFR P00533 3/20 0.43
IGF1R P08069 3/20 0.43
MEN1 O00255 2/20 0.43
ALDH1A1 P00352 2/20 0.43
APP P05067 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6525540 1.00 PLK4 (0.47) PLK4PLK1DHFRERBB2PIM1
SCHEMBL3411693 0.88 PIM1 (0.51) PLK4PLK1ERBB2PIM1PDGFRB
SCHEMBL3711449 0.88 PIM1 (0.51) PLK4PLK1ERBB2PIM1PDGFRB
SCHEMBL6523709 0.86 PIM1 (0.47) PLK4PLK1DHFRERBB2PIM1
SCHEMBL6523716 0.86 PIM1 (0.47) PLK4PLK1DHFRERBB2PIM1
SCHEMBL6523701 0.86 PIM1 (0.47) PLK4PLK1DHFRERBB2PIM1
SCHEMBL3712387 0.83 CHEK1 (0.52) PLK4PLK1PIM1PDGFRBRET
SCHEMBL3712390 0.83 CHEK1 (0.52) PLK4PLK1PIM1PDGFRBRET
SCHEMBL3791289 0.82 KIT (0.49) PLK4PLK1ERBB2PIM1PDGFRB
SCHEMBL12795194 0.82 KIT (0.49) PLK4PLK1ERBB2PIM1PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765748-B2 Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer UNIVERSITY HEALTH NETWORK (CA) 2014-07-01 US disclosed
US-20110065702-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER UNIVERSITY HEALTH NETWORK 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065702-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER TNNI3K, ABL1, TK1 PLK4 464/4885PLK1 4/4885DHFR 447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.